Cargando…

Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges

Noncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA molecules that are not translated into protein but can convey information encoded in their DNA. Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains challenging. Nevertheles...

Descripción completa

Detalles Bibliográficos
Autores principales: Nava, Victor E., Perera, Pin-Yu, Kumar, Nirbhay, Jain, Maneesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877701/
https://www.ncbi.nlm.nih.gov/pubmed/35214734
http://dx.doi.org/10.3390/vaccines10020276
_version_ 1784658482749767680
author Nava, Victor E.
Perera, Pin-Yu
Kumar, Nirbhay
Jain, Maneesh
author_facet Nava, Victor E.
Perera, Pin-Yu
Kumar, Nirbhay
Jain, Maneesh
author_sort Nava, Victor E.
collection PubMed
description Noncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA molecules that are not translated into protein but can convey information encoded in their DNA. Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains challenging. Nevertheless, the importance of understanding ncRNA is apparent since these molecules regulate gene expression at the transcriptional and post-transcriptional level exerting pleiotropic effects critical in development, oncogenesis, and immunity. NcRNAs have been referred to as “the dark matter of the nucleus”, and unraveling their role in physiologic and pathologic processes will provide vast opportunities for basic and translational research with the potential for significant therapeutic progress. Consequently, strong efforts are underway to exploit the therapeutic utility of ncRNA, some of which have been approved by the US Food and Drug Administration and the European Medicines Agency. The use of ncRNA therapeutics (or “vaccines” if defined as anti-disease agents) may result in improved curative strategies when used alone or in combination with existing treatments. This review will focus on the role of ncRNA therapeutics in prostatic carcinoma while exploring basic biological aspects of these molecules that represent about 97% of the transcriptome in humans.
format Online
Article
Text
id pubmed-8877701
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88777012022-02-26 Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges Nava, Victor E. Perera, Pin-Yu Kumar, Nirbhay Jain, Maneesh Vaccines (Basel) Review Noncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA molecules that are not translated into protein but can convey information encoded in their DNA. Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains challenging. Nevertheless, the importance of understanding ncRNA is apparent since these molecules regulate gene expression at the transcriptional and post-transcriptional level exerting pleiotropic effects critical in development, oncogenesis, and immunity. NcRNAs have been referred to as “the dark matter of the nucleus”, and unraveling their role in physiologic and pathologic processes will provide vast opportunities for basic and translational research with the potential for significant therapeutic progress. Consequently, strong efforts are underway to exploit the therapeutic utility of ncRNA, some of which have been approved by the US Food and Drug Administration and the European Medicines Agency. The use of ncRNA therapeutics (or “vaccines” if defined as anti-disease agents) may result in improved curative strategies when used alone or in combination with existing treatments. This review will focus on the role of ncRNA therapeutics in prostatic carcinoma while exploring basic biological aspects of these molecules that represent about 97% of the transcriptome in humans. MDPI 2022-02-11 /pmc/articles/PMC8877701/ /pubmed/35214734 http://dx.doi.org/10.3390/vaccines10020276 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nava, Victor E.
Perera, Pin-Yu
Kumar, Nirbhay
Jain, Maneesh
Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
title Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
title_full Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
title_fullStr Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
title_full_unstemmed Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
title_short Noncoding-RNA-Based Therapeutics with an Emphasis on Prostatic Carcinoma—Progress and Challenges
title_sort noncoding-rna-based therapeutics with an emphasis on prostatic carcinoma—progress and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877701/
https://www.ncbi.nlm.nih.gov/pubmed/35214734
http://dx.doi.org/10.3390/vaccines10020276
work_keys_str_mv AT navavictore noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges
AT pererapinyu noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges
AT kumarnirbhay noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges
AT jainmaneesh noncodingrnabasedtherapeuticswithanemphasisonprostaticcarcinomaprogressandchallenges